Oxytocin
Compoundable (503A)Hormone
Based on public 503A guidance, a compounding pathway appears to exist with a valid, patient-specific prescription. The closest thing to a green light in this dataset — but that's our reading of public sources, not a legal opinion, so confirm with counsel before relying on it.
Not legal advice. Every status on this page is our own reading of public FDA guidance, shortage listings, and committee materials — it has not been reviewed by an attorney and is not a legal determination. "Contested" means pharmacies and regulators publicly disagree, not that we're resolving the disagreement. Verify independently, and check with counsel, before relying on any entry here.
Current status
Permitted under 503A with documented need and a valid prescription.
Last changed: 2026-01-01